Focus on behavioral interventions to prevent HIV transmission has been unsuccessful but the more recent intervention of using antiretroviral drugs has more promise, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.
Focus on behavioral interventions to prevent HIV transmission has been unsuccessful but the more recent intervention of using antiretroviral drugs has more promise, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.
Transcript
Why have previous HIV/AIDS prevention programs been ineffective?
For years, we focused on behavioral interventions. Which worked in some cases, but not all. We have sexually transmitted infections because behavioral interventions haven't been as successful as we might like them to be. The more recent intervention is the use of antiretroviral drugs for prophylaxis. So that is taking high-risk individuals and putting them on an antiretroviral drug to prevent HIV acquisition. If they're adherent, it does block it. But nonadherence is always, again, a behavioral issue. So that's something that has to be dealt with.
The second part is, even though we know PrEP, or pre-exposure prophylaxis works, a lot of countries haven't approved it. And it is a cost-effective measure, but the policies and the politics behind licensure and use and recommendation of these drugs in many countries of the world has lagged. And I think that is in part one of the reasons why we continue to see a rise in HIV infection in those countries.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More